tbuckley/cabot-search huggingface dataset:
Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia
Authors: Akin Akinc, Amy Chan-Daniels, Alfica Sehgal, Don Foster, Brian R Bettencourt, Julia Hettinger, Tim Racie, Justin Aubin, Satya Kuchimanchi, Hila Epstein-Barash, Tomoko Nakayama
Journal: Blood (2011)
Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse
Authors: Lueder Hinrich Meyer, Andrea Zangrando, Sarah M. Eckhoff, Manon Queudeville, Elena Vendramini, Giuseppe Basso, Geertruy te Kronnie, Klaus-Michael Debatin
Journal: Blood (2008)
P3-149: Non–small–cell lung cancer in women: clinical and molecular aspects
Authors: Editta Baldini, Franca Melfi, Laura Boldrini, Simona Doria, Cristina Pennucci, Carmelo Tibaldi, Silvia Gisfredi, Silvia Ursino, Cinzia Orlandini, Gabriella Fontanini
Journal: Journal of Thoracic Oncology (2007)
Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment
Authors: David S Siegel, Katja C. Weisel, Meletios A. Dimopoulos, Rachid Baz, Paul G. Richardson, Michel Delforge, Kevin Song, Jesus San Miguel, Philippe Moreau, Xin Yu, Kevin Hong, Lars Sternas, Mohamed H Zaki, Antonio Palumbo
Journal: Blood (2015)
P2-188: Upper lobe lesions dominate in patients with long term survival of non-surgically treated non small cell lung cancer
Authors: Daniel D. Karp, Jan M. Hanneken, Sarah H. Taylor, Suyu Liu, Ewan D. Johnson, Ignacio I. Wistuba, Stephen G. Swisher, Reginald Munden, David J. Stewart
Journal: Journal of Thoracic Oncology (2007)
Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP.
Authors: P. E. Schwartz, M. G. Glasgow, H. Yu, T. Rutherford, M. Azodi, D. Silasi, A. Santin
Journal: Journal of Clinical Oncology (2010)

e15511 Background: To determine if AS EOC pts evaluated by gynecologic oncologists at one institution and believed not to be surgically cytoreducible (SC) to ≤ 1 cm diameter of residual disease (RD) had a significantly different PFS and OS with NACT (CP) followed by cytoreductive surgery compared to (AS) EOC pts believed to be SC to ≤ 1 cm RD with USC followed by CP. Methods: 221 USC pts (stage IIIC-169, IV-52) and 95 NACT pts (stage III-40, IV-55) treated between 1996 and 2009 were retrospectively reviewed. NACT pts received a median of 6 cycles of C (AUC 6) and P (175 mg/M2) prior to surgery. All NACT pts had imaging findings compatible with AS nonoptimally SC EOC and pathology consistent with EOC. Kaplan-Meier curves were performed for survival analyses. A student T-test was used to compare clinical variables. Results: The PFS and OS for Stage IIIC NACT pts (median 32.5 mos. and 47.5 mos. respectively) was not statistically different than USC pts (median 19.5 and 45.7 mos. respectively; p = 0.099 and 0.918 respectively). The PFS and OS for stage IV NACT pts (median 15.6 and 25.8 mos. respectively) was not statistically different than USC pts (median 13.0 and 48.5 mos.) (p = 0.841and 0.701 respectively). Pts who had no RD at the completion of their initial surgery (NACT 72.8%, USC 43.8%) had statistically improved OS and PFS compared to those with residual tumor. Stage IIIC NACT pts had significantly less postoperative hospital days (5.9 vs. 8.5), blood loss (487 vs. 909 cc) and transfusions (0.6 vs. 1.4) than USC pts. Stage IV NACT pts+ had significantly less hospital days (7.3 vs. 9.8) and blood loss at surgery (413 vs 689) than USC pts. Conclusions: NACT is an appropriate option for AS EOC pts who appear to be non-optimally SC with upfront surgery. No significant financial relationships to disclose.
Primary female breast sarcoma: Clinicopathological features, treatment and prognosis.
Authors: Ming Yin, Heath B. Mackley, Joseph J. Drabick, Harold A. Harvey
Journal: Journal of Clinical Oncology (2016)

11031 Background: Primary breast sarcoma (PBS) is an extremely rare and heterogeneous group of malignancies with limited publications confined to small retrospective case reviews and case reports. Optimal care is poorly defined because information from previous studies is insufficient and inconsistent. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results Program for the years 1973–2012 (n = 785). Stringent inclusion criteria were applied. Analyses of patient, pathologic, and treatment characteristics were performed to determine clinicopathological characteristics of PBS and estimate their associations with overall survival (OS) and cancer-specific survival (CSS). Results: Median age of PBS was 50-60 years and median OS was 108 months. Histologically, the main subtype was angiosarcoma (n = 252). Osteosarcoma and fibrosarcoma/liposarcoma showed the worst and the best prognosis, respectively. Aging, multiple breast location involvement, tumor histology, tumor grade and increased tumor spread were associated with poor survival outcomes. There was a substantially increased non-cancer death risk after 48 months. We then validated AJCC 7th staging system for soft tissue sarcoma in PBS and found unknown grade of tumor (Gx) was associated with significantly worse prognosis, compared with lower grade of G1/G2 (adjHR 2·34 [95% CI 1·63-3·34]). Mastectomy was associated with worse survival outcomes compared with breast conservative surgery (BCS) (adjHR 2·12 [95% CI, 1·58–2·85]) in whole M0 patients and in subgroups by tumor size, tumor grade, tumor histology or radiation history. Adjuvant radiation improved survival outcomes in patients with tumor size > 5 cm (adjHR 0·63 [95% CI, 0·43–0.91]), but not in patients with tumor size ≤ 5 cm. Finally, a new prognostic model using patient and pathological features was developed. Conclusions: There was a substantially increased non-cancer death risk after 48 months. Gx is a poor prognostic factor, compared with G1/G2. Optimal surgical therapy should strive for R0 resection by BCS whenever possible. Adjuvant radiation should be considered in patients with tumor size over 5 cm.
P1-281: Clinical features of bronchial carcinoid tumor- 10 years experience (1996-2006)
Authors: Dragana Jovanovic, Nada Vasic, Ruza Stevic, Spasoje Popevic, Marta Velinovic, Natalija Samardzic, Sanja Dimic, Dragana Maric
Journal: Journal of Thoracic Oncology (2007)
A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma—Final results
Authors: D. N. Korones, M. Benita-Weiss, T. Coyle, P. Bushunow, L. Mechtler, H. S. Friedman
Journal: Journal of Clinical Oncology (2006)

1565 Background: Although temozolomide has proven activity in patients with high and low grade gliomas, many patients do not respond, and for those who do, responses are often short-lived. We therefore undertook a trial of temozolomide in combination with oral VP-16 (etoposide) for patients with recurrent glioma. Methods: Patients were eligible for the study if they had recurrence of a glioma (glioblastoma [GBM], anaplastic glioma, or low-grade glioma), were ≥ 18 years of age, had a WHO score of 0–2, and had not received prior therapy with temozolomide or oral VP-16. All patients received temozolomide, 150 mg/m 2 /d days 1–5 and oral VP-16, 50 mg/m 2 /d days 1–12 (based on the maximum tolerated dose established in a previous phase 1 study [Cancer 2003, 97 (8); 1963–68.]). Cycles were repeated every 28 days for up to 12 cycles. All patients received prophylaxis for pneumocystis. Results: Fifty-one patients were enrolled - 32 with glioblastoma, 12 with anaplastic gliomas, and 7 with low-grade glioma. Median age was 52 years (21–76), and 67% were male. Forty-one were enrolled at first and 10 at second recurrence. Fifty had had prior radiation, and 30 of these 50 patients had also received prior chemotherapy. Of the 32 subjects with GBM, 4 had a PR (12.5%), 13 (41%) SD, 13 (41%) PD, and 2 were not evaluable because of deterioration prior to imaging. The median progression-free survival (PFS) was 2 mo. (0–51+ mo), and the 6 mo. PFS was 19%. Of the 12 patients with anaplastic gliomas, 2 had a PR (16%), 7 SD (58%), 2 PD (16%) and one was not evaluable. Their median PFS was 5.5 mo, and the 6 mo. PFS was 50%. Of the seven subjects with low grade gliomas, 4 had a PR, 2 SD, and 1 PD. Their median PFS was 5 mo. (0–12) and 6 mo. PFS was 57%. Of the entire cohort, two patients developed fever and neutropenia and died of pseudomonas sepsis. Another two patients were prematurely withdrawn from the study due to toxicity (one for grade 4 neutropenia and a second for grade 2 diarrhea). Conclusions: In this population of previously treated patients with recurrent glioma, the combination of oral VP-16 and temozolomide has only modest efficacy and significant toxicity. The results of this study suggest that in this setting, the combination offers no advantage over either agent used alone. [Table: see text]
Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA
Authors: Kuan-hui Xiang, Eleftherios Michailidis, Hai Ding, Ya-qin Peng, Ming-ze Su, Yao Li, Xue-en Liu, Viet Loan Dao Thi, Xian-fang Wu, William M. Schneider, Charles M. Rice, Hui Zhuang, Tong Li
Journal: Journal of Hepatology (2016)
Congenital Zika syndrome: time to move from case series to case-control studies and data sharing
Authors: Patrick Gérardin, Hanitra Randrianaivo, Bruno Schaub, Raymond Césaire, Bérénice Doray, A Désirée LaBeaud
Journal: BMJ (2016)

We welcome the paper reporting seven cases of congenital Zika syndrome (CZS) with arthrogryposis.1 Mounting evidence that Zika virus infection in early gestation causes brain damage shows that Zika associated arthrogryposis may be neurogenic. In agreement, the mechanisms underlying the CZS phenotype would be a tropism of the virus to neuronal cells,2 3 or vascular disorders, as in the …
Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States
Authors: Ruben A. Mesa, Carole B. Miller, John O. Mascarenhas, Maureen Thyne, Sara Goldberger, Dilan C. Paranagama, Shreekant V. Parasuraman, Salman Fazal, Ahmad B. Naim, James Mangan
Journal: Blood (2015)
P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C
Authors: J. Ampuero, L. Rojas, J.A. Del Campo, J.L. Calleja, J. Crespo, X. Forns, R. Andrade, M. Buti, I. Fernández, R. Millán, M. Romero-Gómez
Journal: Journal of Hepatology (2015)
P3-250: Adrenalectomy for metastases from lung cancer
Authors: Romero V. Laura, Deu M. María, Canela C. Mercedes, Lopez S. Iker, Baena F. Juan Antonio, Teixidor S. Juan, Sole M. Juan, Jauregui A. Alberto, Rodriguez R. Roberto, Maestre A. José Antonio
Journal: Journal of Thoracic Oncology (2007)
Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC.
Authors: E. Sanmartin, E. Jantus, A. Blasco, R. Sirera, C. Caballero, S. Gallach, R. M. Bremnes, N. del Pozo, A. Berrocal, C. Camps
Journal: Journal of Clinical Oncology (2010)

10623 Background: VEGF ligands and receptors have an important role in tumor angiogenesis. An increased expression of these angiogenic factors in tumor or serum/plasma is associated with metastasis and poor prognosis. The aim of this study is to investigate the usefulness of the quantification of soluble VEGF-A and VEGFR-2 as biomarkers in advanced NSCLC. Methods: We studied 458 advanced NSCLC (stages IIIB-IV) patients treated with cisplatin and docetaxel and 89 healthy age-matched controls. Blood samples were collected before chemotherapy and VEGF-A and VEGFR-2 protein levels were determined by ELISA. All statistical analyses were considered significant at p ≤ 0.05. Results: VEGF-A and VEGFR-2 levels were significantly higher in patients than controls; VEGF-A: 105.92 ± 5.30 pg/mL vs 26.17 ± 5.35 pg/mL, respectively; p < 0.0001; and VEGFR-2: 8,346 ± 120 pg/mL vs 6,903 ± 144 pg/mL, respectively; p < 0.0001). The area under the ROC curve was 0.858 for VEGF-A and 0.744 for VEGFR-2, indicating that both variables are suitable biomarkers for discrimination between the groups. Patients with high VEGFR-2 plasma levels (75 percentile) show a significantly longer time to progression (TTP, p = 0.029). On the other hand, high levels of soluble VEGF-A (75 percentile) correlates with a poor overall survival (OS, p = 0.026). A subgroup characterized by a combination of high levels of soluble VEGF-A and low levels of soluble VEGFR-2 had the worse prognosis regarding TTP (p = 0.042) and OS (p = 0.003), when compared with other possible combinations of markers. Conclusions: In advanced NSCLC, soluble levels of VEGF-A and VEGFR-2 are significantly higher in patients than age-matched controls. The combination of high plasma VEGF-A and low VEGFR-2 identified a NSCLC subgroup with a poorer prognosis, that may benefit from additional antiangiogenic therapy. No significant financial relationships to disclose.
T<scp>ranslational</scp> A<scp>dvances in the</scp> F<scp>ield of</scp> P<scp>ulmonary</scp> H<scp>ypertension</scp>.From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs
Authors: Soni Savai Pullamsetti, Rajkumar Savai, Werner Seeger, Elena A. Goncharova
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.
Authors: C. D. Weekes, P. LoRusso, V. Ramakrishnan, L. M. Shih, W. C. Darbonne, P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, A. Patnaik
Journal: Journal of Clinical Oncology (2011)

3050^ Background: Neuropilin-1 (NRP1) is involved in remodeling and maturation of blood vessels. MNRP1685A is a human monoclonal antibody that blocks binding of ligands, including VEGF, VEGF-B and PlGF, to NRP1 thereby maintaining vessel immaturity and VEGF-dependency. This study sought to determine whether MNRP1685A can be safely combined with bevacizumab with or without paclitaxel. Methods: Patients received escalating doses of MNRP1685A with 15 mg/kg bevacizumab (every 3 weeks) in Arm A, or with 10 mg/kg bevacizumab (every two weeks) and 90 mg/m2 paclitaxel (weekly, 3 of 4 weeks) in Arm B. Objectives were to determine safety, pharmacokinetics (PK), pharmacodynamics (PD), and the maximum tolerated dose of MNRP1685A in both arms. Results: 14 patients were enrolled into dose-escalation cohorts (3+3 design) of 7.5, 15, 24 and 36 mg/kg in Arm A, and 10 patients into cohorts of 12 and 16 mg/kg in Arm B. As in phase Ia, grade 1 or 2 acute infusion reactions (AIRs, mainly rash and pruritus, premedication included dexamethasone) and transient platelet reductions within 2-8 days following MNRP1685A infusion were observed. Treatment-related grade 3-5 adverse events (AEs; cut-off date 11/23/10) included 1 sudden death, unknown etiology, at Day 7 in Arm A (36 mg/kg), neutropenia (n=4, all Arm B), proteinuria (n=3), thrombocytopenia (n=2), hypertension (n=2), and one each of fatigue, keratorhexis, and peripheral edema. AEs occurring in ≥25% included AIRs (67%), neutropenia (60%, Arm B), hypertension (29%), fatigue (29%), epistaxis, nausea and proteinuria (25% each). 5 of 5 patients treated beyond 5 cycles developed grade ≥2 proteinuria. MNRP1685A PK was similar to phase Ia, but increases in PD biomarker placental growth factor were higher and sustained longer. Conclusions: The safety profile of MNRP1685A when combined with bevacizumab with or without paclitaxel was evaluated in this Phase Ib study. AIRs were frequent but tolerable with premedication. Platelet reductions were frequent, transient and recoverable. A higher than expected rate of clinically significant proteinuria, resulting in hold or discontinuation of drugs, was observed.
Coronary Artery Disease - Reporting and Data System (CAD-RADS)
Authors: Ricardo C. Cury, Suhny Abbara, Stephan Achenbach, Arthur Agatston, Daniel S. Berman, Matthew J. Budoff, Karin E. Dill, Jill E. Jacobs, Christopher D. Maroules, Geoffrey D. Rubin, Frank J. Rybicki, U. Joseph Schoepf, Leslee J. Shaw, Arthur E. Stillman, Charles S. White, Pamela K. Woodard, Jonathon A. Leipsic
Journal: JACC. Cardiovascular imaging (2016)
OC-078 The diagnostic accuracy of colonocyte dna quantification in colorectal cancer diagnosis using a novel device
Authors: L Mahadavan, I Daniels, D Cotter, A Loktionov, A Llewelyn, A Shore, W Hamilton
Journal: Gut (2010)

<h3>Introduction</h3> Survival from colorectal carcinoma (CRC) has not recently improved in the UK despite various initiatives including rapid investigation clinics and the national screening programme. It can be a difficult disease to diagnose. A new diagnostic device (Colonix®) that obtains an imprint of the rectal mucosa has been developed. Early laboratory and pilot studies suggest that the amount of colonocyte DNA correlates well with colorectal pathology. The aim of this study was to assess the diagnostic accuracy of the Colonix® device in identifying CRC in patients with moderate to high risk of colorectal cancer. <h3>Methods</h3> Patients were referred by their primary care physicians for further investigation according to the NICE guidelines. Participants completed a symptom questionnaire, had routine blood tests, faecal occult blood test (FOBT) and had a Colonix® test in clinic. The main outcome of the study was the presence of CRC. This was determined histologically by conventional investigation. The quantity of DNA in the sample was measured by investigators blinded to the outcome. <h3>Results</h3> 828 patients entered the study: 717 received a Colonix® test. Three were lost to follow-up, leaving 714 patients for analysis of whom 72 (10.1%) had a CRC. The mean (SD) age of those with cancer was 74 years (9.7), and those without 70 (12.4) years. 42 (58%) of the cancers were in males whereas 277 (43%) of those without cancer were male. The mean (SD) DNA score in cancer cases was 7.5 (7.3) ng/ml, and in those without cancer 4.4 (5.6) ng/ml, a significant difference (p&lt;0.001). In univariable logistic regression the odds-ratio of each ng/ml of the DNA score was 1.07 (95% CI 1.04 to 1.11). Using the DNA score alone, the area under the ROC curve was 0.65. The area under the ROC curve improved to 0.87 in multivariable analysis using DNA score, age, mean cell volume (MCV), carcino-embryonic antigen (CEA), positive faecal occult blood test and rectal bleeding. <h3>Conclusion</h3> Colonocyte DNA scores obtained using a Colonix® test, have considerable ability to identify colorectal cancer in the referred population when combined with the results of other simple investigations.
MicroRNA‐130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Mesangial Cells
Authors: Xiao Han, Yan Wang, Xiaoyan Zhang, Yuting Qin, Bo Qu, Lingling Wu, Jianyang Ma, Zhenyuan Zhou, Jie Qian, Min Dai, Yuanjia Tang, Edward K. L. Chan, John B. Harley, Shiyu Zhou, Nan Shen
Journal: Arthritis & Rheumatology (2016)

Type I interferon (IFN) is a critical pathogenic factor during the progression of lupus nephritis (LN). Although microRNAs (miRNAs) have been shown to control the IFN response in immune cells in LN, the role of miRNAs in resident renal cells remains unclear. We undertook this study to investigate the role of microRNA-130b (miR-130b) in the IFN pathway in renal cells as well as its therapeutic effect in LN.Kidney tissues from patients and (NZB × NZW)F1 lupus-prone mice were collected for detecting miR-130b levels. Primary renal mesangial cells (RMCs) were used to determine the role of miR-130b in the IFN pathway. We overexpressed miR-130b by administering miR-130b agomir in a mouse model of IFNα-accelerated LN to test its therapeutic efficacy.Down-regulated miR-130b expression was observed in kidney tissues from patients and lupus-prone mice. Further analysis showed that underexpression of miR-130b correlated negatively with abnormal activation of the IFN response in LN patients. In vitro, overexpressing miR-130b suppressed signaling downstream from the type I IFN pathway in RMCs by targeting IFN regulatory factor 1 (IRF-1). The opposite effect was observed when endogenous miR-130b expression was inhibited. The inverse correlation between IRF1 and miR-130b levels was detected in renal biopsy samples from LN patients. More importantly, in vivo administration of miR-130b agomir reduced IFNα-accelerated progression of LN, with decreased proteinuria, lower levels of immune complex deposition, and lack of glomerular lesions.MicroRNA-130b is a novel negative regulator of the type I IFN pathway in renal cells. Overexpression of miR-130b in vivo ameliorates IFNα-accelerated LN, providing potential novel strategies for therapeutic intervention in LN.
A 7 gene set associated with chronic hypoxia of universal prognostic importance in hepatocellular carcinoma
Authors: Hannah van Malenstein, Olivier Gevaert, Louis Libbrecht, A Daemen, Joke Allemeersch, Frederik Nevens, Eric Van Cutsem, David Cassiman, Bart De Moor, Chris Verslype, Jos van Pelt
Journal: Journal of Hepatology (2010)
Hairy Cell Leukemias (HCL) with Unmutated V-Genes Have a Poorer Response to Single Agent 2CdA Than HCL with Mutated V-Genes.
Authors: Francesco Forconi, Elisa Sozzi, Donatella Raspadori, Francesca Toraldo, Marzia Defina, Francesco Zaja, Luigi Rigacci, Caterina Stelitano, Andrea Gallamini, Piero Galieni, Tamara Intermesoli, P.M. Stefani, Alfonso Zaccaria, Mariapia Lenoci, Monica Bocchia, Francesco Lauria
Journal: Blood (2006)
Gastrointestinal Findings in Patients with Autoimmune Pancreatitis
Authors: T. Kamisawa, N. Egawa, H. Nakajima, K. Tsuruta, A. Okamoto, Y. Hayashi, N. Funata
Journal: Endoscopy (2005)

Background and Study Aims: Autoimmune pancreatitis (AIP) is a condition that has been proposed as a clinical entity only fairly recently. Its pathogenesis involves autoimmune mechanisms. Although the radiological findings in patients with AIP have been well evaluated, few studies have focused on the gastrointestinal findings in these patients. The aim of this study was to explore the endoscopic and histological findings in the gastrointestinal tract in patients with autoimmune pancreatitis. Patients and Methods: The endoscopic findings in the stomach (n = 10), the duodenum (n = 18), the major duodenal papilla (n = 18), and the colon (n = 5) in 24 patients with AIP were reviewed. These were compared with the results of histological examination of gastric mucosa (n = 13), duodenal mucosa (n = 9), the major duodenal papilla (n = 3), and colonic mucosa (n = 3) in these patients. All these specimens were subjected to immunohistochemical study using anti-IgG4 antibody. Results: Foci of slightly pale, thickened mucosa with loss of visible vascular pattern were observed in the stomach in four patients and in the colon in two patients on endoscopy. Slight or moderate swelling of the major duodenal papilla was detected in five patients. Slight to moderate lymphoplasmacytic infiltration was observed in the lamina propria of the gastric and colonic mucosa, and of the major duodenal papilla. Heavy infiltration with IgG4-positive plasma cells (>10 cells per high-power field) was observed in the lamina propria of the stomach in seven patients, of the colon in two patients, and of the major duodenal papilla in three patients; this was not observed in the control patients, who had other diseases. Conclusions: Although there were no specific endoscopic findings in the stomach or colon in patients with autoimmune pancreatitis, foci of slightly pale, thickened mucosa with loss of visible vascular pattern were observed in some cases. This indistinct change seen on endoscopy appears to be due to heavy infiltration with IgG4-positive plasma cells, associated with CD4- or CD8-positive T lymphocytes, in the lamina propria of the gastric or colonic mucosa.
Does symmetry of the aortic outflow velocity profile reflect contractile function in coronary artery disease? An automated analysis using mathematical modelling
Authors: Maja Čikeš, Hrvoje Kalinić, Aigul Baltabaeva, Sven Lončarić, Chirine Parsai, Jadranka Šeparović Hanževački, Ivo Čikeš, Sutherland, George, Bart Bijnens
Journal: Circulation (2008)